Recent news on Naglazyme

BioMarin Announces First Quarter 2007 Financial Results  -  Apr 30, 2007
PR Newswire (press release),..."Strong Naglazyme sales are driving better than expected bottom-line results and fueling the development of our pipeline. Based on the upside to first

BioMarin's Big Moves: Fool by Numbers  -  May 3, 2007
Motley FoolRevenues increased 65.3% driven by rise in sales of Naglazyme. BioMarin's other drug, Aldurazyme, marketed by Genzyme (Nasdaq: GENZ), also turned in solid

BioMarin to Host First Quarter 2007 Financial Results Conference ...  -  Apr 20, 2007
PharmaLive.com (press release),Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin,

State steps in to help Sophie  -  Apr 17, 2007
Courier Mail,Sophie's doctors want to treat her with the unsubsidised drug Naglazyme, but at $1850 a vial, the cost is outside the reach of the Nance family who had

BioMarin Announces Closing of $324875000 Public Offering of Senior ...  -  Apr 24, 2007
PharmaLive.com (press release),Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin,

BioMarin to Present at the Cowen and Company 27th Annual Health ...  -  27 Mar 2007
Drug Newswire (press release),Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin,

Mostly Good From BioMarin  -  Feb 27, 2007
Motley FoolIt received marketing approval in the European Union for one of its key drugs, Naglazyme, and prepared the way for possible FDA approval of another drug

BioMarin to Present at the Lehman Brothers Tenth Annual Global ...  -  Mar 13, 2007
PharmaLive.com (press release),Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin,

BioMarin's Bionic Report: Fool by Numbers  -  Feb 26, 2007
Motley FoolRevenues have shot up by 132.4% due to increased revenues from Naglazyme and Aldurazyme. Net loss has narrowed for the quarter on back of better revenues

Fighting for life  -  Feb 23, 2007
Courier Mail,Naglazyme, produced by US-based BioMarin Pharmaceuticals Inc, costs $1850 a vial, which means her parents will have to find $200000 for the first year.

BioMarin Announces Fourth Quarter and Full Year 2006 Financial Results  -  Feb 22, 2007
Drug Newswire (press release),Looking ahead in 2007, we expect continuing growth of Naglazyme and Aldurazyme sales to substantially offset research and development spending for ongoing

BioMarin Pharmaceutical "outperform," estimates raised  -  Feb 21, 2007
newratings.comBioMarin Pharmaceutical has issued its net loss guidance in-line with the estimates at $20-$25 million and its Naglazyme revenue guidance ahead of the

BioMarin Says Hypertension Treatment Failed in Trial (Update2)  -  Feb 20, 2007
BloombergSales of Naglazyme, approved for US sales in May 2005 to treat a metabolic disorder, quadrupled to $16.3 million, contributing to a doubling in revenue to

BioMarin Sees Higher Drug Sales in 2007  -  Feb 20, 2007
Forbes,Biopharmaceutical company BioMarin Pharmaceutical Inc. on Tuesday said it expects sales of its Naglazyme and Aldurazyme enzyme-replacement therapies to grow

BioMarin Announces Date and Time Change of Fourth Quarter and Full ...  -  Feb 20, 2007
PharmaLive.com (press release),Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin,

BioMarin losses fall  -  Feb 20, 2007
San Francisco Business Times,Sales of its drug Naglazyme, a treatment for mucopolysaccharidosis VI, rose to $16.3 million in the quarter, up from $12.9 million a year ago in the same

BioMarin shares fall on study data  -  Feb 20, 2007
BusinessWeek...sales and narrowed its loss in the fourth quarter. The company also forecast higher sales of Naglazyme and Aldurazyme enzyme replacement therapies in 2007.

BioMarin shares fall on quarterly results, study data  -  Feb 20, 2007
MarketWatchBioMarin also forecast 2007 sales of Naglazyme in a range of $74 million to $78 million and joint venture sales of Aldurazyme in a range of $115 million to

BioMarin 4th-Quarter Net Loss Narrows  -  Feb 20, 2007
Houston Chronicle,Product revenue, including sales of enzyme-replacement therapy drugs Naglazyme and Aldurazyme, jumped to $16.3 million from $4.2 million during the

UPDATE 1-TABLE-BioMarin Q4 loss narrows  -  Feb 20, 2007
Reuters...--BioMarin sees 2007 net sales for Naglazyme of $74 million to $78 million and Aldurazyme sales by joint venture with Genzyme Corp. (GENZ.

BioMarin Announces Date and Time Change of Fourth Quarter and Full ...  -  Feb 16, 2007
PR Newswire (press release),Naglazyme(R) is a registered trademark of BioMarin Pharmaceutical Inc. Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

Remaining $51.4 Million of Convertible Notes Due 2008 Converted ...  -  Jan 29, 2007
Yahoo! News (press release)Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin,

BioMarin to Present at the JPMorgan 25th Annual Healthcare Conference  -  Jan 8, 2007
PharmaLive.com (press release),Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin,

BioMarin to Present at the JPMorgan 25th Annual Healthcare Conference  -  Jan 7, 2007
PR Newswire (press release),Naglazyme(R) is a registered trademark of BioMarin Pharmaceutical Inc. Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

Zacks Bull and Bear of the Day Highlights: BioMarin, Solectron ...  -  Dec 28, 2006
American Digital Networks (press release),The company recently gained FDA and European approval for another product, Naglazyme, for the treatment of MPS-VI and Orapred ODT for asthma in children.

A costly second chance for little Isaac  -  Dec 26, 2006
Globe and Mail,It is that of a preschooler thriving after receiving one of the most expensive drugs in the world -- Naglazyme -- the only treatment for Maroteaux-Lamy

A costly second chance for little Isaac  -  26 Dec 2006
Globe and Mail,It is that of a preschooler thriving after receiving one of the most expensive drugs in the world -- Naglazyme -- the only treatment for Maroteaux-Lamy

BioMarin drug does well in Phase III study  -  Dec 18, 2006
San Francisco Business Times,BioMarin has two drugs already approved by the FDA: Naglazyme and Aldurazyme, both treatments for types of mucopolysaccharidosis.

Cross the Bridge to BioMarin  -  Dec 6, 2006
TheStreet.comBioMarin's Naglazyme for MPS VI and Aldurazyme for MPS I are the first drugs approved for these indications. The two were granted orphan status,

BioMarin Calls Remaining $51.4 Million of Convertible Notes Due 2008  -  Dec 22, 2006
PR Newswire (press release),Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin,

BioMarin Announces Third Quarter 2006 Financial Results  Nov 1, 2006
Robust Naglazyme Launch Drives Better Bottom-Line Results Conference Call and Webcast to Be Held Today at 5:00 pm ET (23:00 CET) NOVATO, Calif., Nov. ... -PR Newswire (press release), BioMarin Announces Third Quarter 2006 Financial Results  Nov 1, 2006
Jean-Jacques Bienaime, Chief Executive Officer of BioMarin commented, "The launch of Naglazyme in the US, Europe and some international markets continues to ... -PR Newswire (press release), BioMarin's in Good Health  Nov 2, 2006
...rose a whopping 227% year over year to $25 million, thanks to strong sales from the company's two enzyme replacement therapies, Naglazyme and Aldurazyme. ... -Motley Fool BioMarin Bumped Up: Fool by Numbers  Nov 2, 2006
...of $0.08. Revenue increases were mainly due to stronger product sales, particularly in Aldurazyme and Naglazyme. Restrained spending ... -Motley Fool BioMarin Announces Marketing Approval for Aldurazyme in Japan  Nov 1, 2006
Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, and ... -PharmaLive.com (press release), BioMarin Pharmaceutical initiated with "buy"  Oct 11, 2006
...a research note published yesterday, the analyst mentions that the company has developed and launched two marketed products, Aldurazyme and Naglazyme, and has ... -newratings.com BioMarin Completes Enrollment of Phase 2 Clinical Study of 6R-BH4 ...  Sep 20, 2006
Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, and ... -PR Newswire

Zacks Analyst Blog Highlights: BioMarin and Acusphere.  Sep 22, 2006
The company recently gained FDA and European approval for another product, Naglazyme, for the treatment of MPS-VI and Orapred ODT for asthma in children. ... -Business Wire

Priced In at Alexion  Sep 1, 2006
...annually. BioMarin's (BMRN - commentary - Cramer's Take) Naglazyme for Maroteaux-Lamy syndrome can cost nearly $400,000. Soliris ... -TheStreet.com

BioMarin to Present at BioCentury's NewsMakers in the Biotech ...  Aug 31, 2006
Approved products include Naglazyme(TM) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, and ... -Yahoo! News

Cross the Bridge to BioMarin  -  Dec 6, 2006
TheStreet.com...reaching adulthood. BioMarin's Naglazyme for MPS VI and Aldurazyme for MPS I are the first drugs approved for these indications. The ...

BioMarin Announces US Launch of Orapred ODT Through Alliant ...  29 Aug 2006
Approved products include Naglazyme(TM) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, and ... -PR Newswire

BioMarin Announces Second Quarter 2006 Financial Results  Aug 2, 2006
Strong Naglazyme Sales Lead to Improved Top- and Bottom-Line Guidance for 2006 Conference Call and Webcast to Be Held Today at 5:00 pm EDT (23:00 CEST) NOVATO ... -PR Newswire

BioMarin Announces Second Quarter 2006 Financial Results  Aug 2, 2006
..."Our launch of Naglazyme is going very well and is exceeding our prior expectations," stated Jean-Jacques Bienaime, Chief Executive Officer of BioMarin. ... -Yahoo! News

BioMarin Narrows Loss in 2nd Quarter  Aug 2, 2006
The company said sales of Naglazyme, an enzyme replacement therapy for a rare debilitating condition that allows carbohydrates to build up and shut down organs ... -MSN Money

BioMarin Q2 Loss Narrows On Higher Revenues; Expects Lower FY06 ...  Aug 3, 2006
...period last year. Naglazyme net revenues rose to $10.3 million from $0.1 million in the prior-year quarter. Orapred net product ... -Trading Markets

Alfimeprase to succeed Genentech's alteplase?  Aug 2, 2006
Other enzyme products followed, including Aldurazyme (laronidase), from Genzyme and BioMarin Pharmaceutical, in 2003, and, in 2005, Naglazyme (galsulfase) from ... -Nature.com (subscription)

StreetInsider.com After-Hours Movers 08/02  Aug 2, 2006
...$23.5 million vs. $15.75 million consensus. Boosts FY06 Naglazyme sales to $40-$44 million (prior guidance of $31-$34M). 24/7 Real ... -StreetInsider.com (subscription)

Boy to get costly drug  Jul 15, 2006
...syndrome. The drug, Naglazyme, costs $300,000 to $1-million annually. "This is life-changing for Isaac," Mr. McFadyen said yesterday. ... -Globe and Mail

BioMarin Pharmaceutical initiated with "neutral"  Jul 20, 2006
...yesterday, the analyst mentions that the company has an impressive enzyme replacement therapy (ERT) franchise due to the Aldurazyme and Naglazyme drugs. ... -newratings.com

BioMarin Initiates Phase 2 Clinical Study Of 6R-BH4 In Poorly ...  Jul 7, 2006
Approved products include Naglazyme(TM) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, and ... -Medical News Today



MPP demands help for ailing boy  May 11, 2006
Without it, the McFadyen family from Campbellford, Ont., will have to move to England where the government covers the drug Naglazyme, which costs a staggering ... - Globe and Mail

BioMarin Announces First Quarter 2006 Financial Results  May 3, 2006
2006 Naglazyme Sales Guidance Increased and 2006 Net Loss Guidance Improved Conference Call and Webcast to Be Held Today at 5:00 pm EDT (23:00 CEST) NOVATO ... - PR Newswire

BioMarin Announces First Quarter 2006 Financial Results  May 3, 2006
...with what we have accomplished in the first quarter of the year, especially the progress we have made with the commercial launch of Naglazyme," stated Jean ... - PR Newswire

‘We're looking for a lifeboat'  Apr 28, 2006
The only drug available to treat the progressive disease, known by the trade name Naglazyme, is so expensive that even its US-based developer and manufacturer ... - Globe and Mail

'We're looking for a lifeboat'  Apr 29, 2006
The only drug available to treat the progressive disease, a medication known by the trade name Naglazyme, is so expensive that even its US-based developer and ... - Globe and Mail

Rodman & Renshaw 3rd Annual Global Healthcare Conference 2006 ...  May 11, 2006
Approved products include Naglazyme(TM) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, and ... - Genetic Engineering News

Biotech firms chase 'orphan' drugs  May 1, 2006
...at the annual banquet of the National Organization for Rare Disorders last week that his company's trial to gain the agency's approval for Naglazyme in June ... - International Herald Tribune

'83 law called big boost for rare-disease drugs  May 1, 2006
Inc., a California biotech firm, told NORD's annual banquet last week that the company's pivotal trial to earn the FDA's approval for Naglazyme in June 2005 ... - Boston Globe

Most, not least, in need  May 1, 2006
Esquimalt, BC -- Isaac McFadyen's parents should do their homework very carefully before moving to Britain for an NHS supply of naglazyme. ... - Globe and Mail

BioMarin Pharmaceutical Inc.'s $297.5M Convertible Subordinated D ...  May 5, 2006
...of two products: (1) Aldurazyme, an enzyme replacement therapy for the treatment of genetic disease mucopolysaccharidosis I (MPS I), and (2) Naglazyme, a drug ... - PharmaLive.com





BioMarin Announces Closing of $295 Million Concurrent Public ...  Mar 30, 2006
Approved products include Naglazyme(TM) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, and ... - PR Newswire

BioMarin’s Shares Move On Phenoptin Phase III Success  Mar 16, 2006
...planning on marketing this product here," Bienaime told BioWorld Today, "because we already have a sales force in place, selling Naglazyme, calling on genetic ... - BioWorld Online (subscription)

Eye On Stocks For Thursday, March 16  Mar 15, 2006
BioMarin to outperform the market by more than 25% over the next 12 months as investors gain confidence in the commercial potential of Naglazyme and Phenoptin. - Forbes



BioMarin Announces Fourth Quarter and Year-End 2005 Financial ...  Feb 23, 2006
During this time, we achieved key company milestones, including the approval of Naglazyme in both the United States and Europe, the completion of the double ... - PR Newswire,

BioMarin Receives Marketing Approval for Naglazyme in European ...  Jan 30, 2006
...(Nasdaq and SWX: BMRN) announced today that the European Commission has granted marketing authorization for Naglazyme(TM) (galsulfase), the first specific ... - MSN Money

BioMarin drug Naglazyme gets EU approval  Jan 30, 2006
...(BMRN.O: Quote, Profile, Research) on Monday said European regulators approved its drug Naglazyme to treat a rare genetic disease with orphan drug status ... - Reuters

BioMarin Receives Marketing Approval for Naglazyme in European ...  Jan 30, 2006
2006 Revenue Guidance for Naglazyme and Aldurazyme Provided Conference Call to be Held Today at 5:00 pm ET (23:00 CET) NOVATO, Calif., Jan. ... - PR Newswire

BioMarin Receives Marketing Approval for Naglazyme in European ...  Jan 30, 2006
...announced today that the European Commission has granted marketing authorization for Naglazyme(TM) (galsulfase), the first specific treatment approved in the ... - PharmaLive.com

BioMarin Receives Marketing Approval for Naglazyme in European ...  Jan 31, 2006
...announced yesterday that the European Commission has granted marketing authorization for Naglazyme(TM) (galsulfase), the first specific treatment approved in ... - DG News

BioMarin Establishes Commercial Operations in Europe  Jan 10, 2006
...announced today that it has established commercial operations in Europe in anticipation of receiving European marketing approval for Naglazyme(TM) (galsulfase ... - PR Newswire

European regulators OK BioMarin drug  Jan 30, 2006
The company also predicted 2006 sales of the Naglazyme drug will range from $28 million to $32 million and forecast year-end sales of its Aldurazyme therapy ... - BusinessWeek

BioMarin Establishes Commercial Operations in Europe  Jan 10, 2006
...announced today that it has established commercial operations in Europe in anticipation of receiving European marketing approval for Naglazyme(TM) (galsulfase ... - PharmaLive.com

(PRN) - Chesapeake Energy Corporation Announces Private Offering ...  Jan 30, 2006
...(PRN) - Myogen to Present at the NASDAQ US Small Cap Conference ... [+. PRN) - BioMarin Receives Marketing Approval for Naglazyme in European Union ... [+. ... - Bolsamania.com

BioMarin Receives FDA Fast Track Designation for Phenoptin for PKU  Jan 25, 2006
Approved products include Naglazyme(TM) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin ... - PR Newswire

Schaeffer's Top and Bottom Ranked Stocks (BMRN, ELNK, LGF)  Jan 12, 2006
...inhabitants. The firm's Naglazyme medication combats Maroteaux-Lamy syndrome, from which only about 1,100 sufferers exist worldwide. ... - Schaeffers Research

Biotechnology Industry Ends 2005 with Breakthrough Product ...  Jan 18, 2006
Some orphan drugs approved are: BioMarin's Naglazyme, an enzyme replacement therapy for mucopolysaccharidosis VI; Tercica Inc.'s Increlex, long-term treatment ... - Yahoo! News

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional